本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 证券代码：300430 证券简称：诚益通 公告编号：2025-015 北京诚益通控制技术集团股份有限公司 关于 2024 年度利润分配预案的公告 1、北京诚益通控制技术集团股份有限公司（以下简称"公司"）拟以 273,047,596 股为基数，向全体股东每 10 股派发现金红利 0.45 元（含税），共派 发现金红利不超过 12,287,141.82 元（含税），不以资本公积金转增股本，不送红 股。剩余未分配利润结转至下一年度。 2、本利润分配方案须经股东大会审议通过后方可实施，存在不确定性，敬请 广大投资者理性投资，注意投资风险。 3、公司现金分红方案不触及《深圳证券交易所创业板股票上市规则》第 9.4 条规定的相关情形。 一、审议程序 （一）董事会审议情况 公司于 2025 年 4 月 23 日召开第五届董事会第十一次会议，经全体董事审议， 全票通过了《关于<公司 2024 年度利润分配预案>的议案》。 （二）监事会审议情况 公司于 2025 年 4 月 23 日召开第五届监事会第十一次会议，经全 ...

Financial Performance - The company's revenue for Q1 2025 was ¥189,301,895.29, a decrease of 29.42% compared to ¥268,203,514.86 in the same period last year[5] - Net profit attributable to shareholders was ¥12,591,771.66, down 59.09% from ¥30,781,307.45 year-on-year[5] - Basic and diluted earnings per share decreased by 54.55% to ¥0.05 from ¥0.11 in the same period last year[5] - The net profit for the current period is 4,897,840.34, compared to 30,602,538.88 in the previous period, reflecting a significant decrease[30] - The total profit for the current period is 2,244,475.05, down from 35,766,817.24 in the previous period[30] - The total comprehensive income for the current period is 4,897,491.41, down from 30,678,454.17 in the previous period[30] Cash Flow - The net cash flow from operating activities improved by 17.98%, reaching -¥43,012,374.11 compared to -¥52,443,691.07 in the previous year[5] - Cash flow from operating activities showed a net outflow of -43,012,374.11, an improvement from -52,443,691.07 in the previous period[33] - Cash flow from investing activities resulted in a net outflow of -62,696,876.94, compared to -59,522,280.02 in the previous period[34] - Cash flow from financing activities recorded a net outflow of -9,490,210.18, contrasting with a net inflow of 34,298,279.32 in the previous period[34] - The company received cash from sales of 258,688,678.48, an increase from 225,253,580.40 in the previous period[33] - The company reported a decrease in other operating cash inflows to 22,150,700.49 from 35,907,132.41 in the previous period[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,590,127,924.52, a slight increase of 0.34% from ¥3,577,825,097.29 at the end of the previous year[5] - Cash and cash equivalents decreased to CNY 242,315,534.63 from CNY 358,761,920.13, a decline of 32.5%[25] - Accounts receivable decreased slightly to CNY 742,839,477.75 from CNY 759,138,216.08, a reduction of 2.1%[25] - Inventory increased to CNY 616,107,487.55, up 10.8% from CNY 556,226,345.69[26] - Total liabilities increased to CNY 1,350,914,243.21 from CNY 1,343,508,907.39, an increase of 0.5%[28] - The total equity attributable to shareholders increased to CNY 2,244,661,421.13 from CNY 2,232,069,998.40, a rise of 0.6%[28] Operating Costs and Expenses - The company reported a 31.90% decrease in operating costs, aligning with the decline in revenue[16] - Total operating costs for the current period are CNY 184,631,032.98, down 20.3% from CNY 231,592,230.32 in the previous period[29] - Research and development expenses increased by 57.29% compared to the same period last year, indicating a focus on innovation[16] - Research and development expenses increased to CNY 27,393,774.79, a rise of 57.2% compared to CNY 17,416,024.04 in the previous period[29] Shareholder Information - The weighted average return on equity decreased to 0.56% from 1.42% year-on-year, indicating reduced profitability[5] - The company received government subsidies amounting to ¥917,601.31 during the reporting period[7] - The company plans to unlock shares for certain executives on January 1, 2026, totaling 13,193,387 shares[24]

Dividend and Financial Performance - The company plans to distribute a cash dividend of 0.45 RMB per 10 shares to all shareholders, based on a total of 273,047,596 shares[4]. - The company's operating revenue for 2024 was ¥958,124,441.96, a decrease of 18.49% compared to ¥1,175,510,911.00 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥96,548,437.45, down 43.23% from ¥170,081,900.87 in 2023[20]. - The net cash flow from operating activities significantly increased to ¥231,009,966.21, a rise of 1,430.18% compared to ¥15,096,927.76 in 2023[20]. - The total assets at the end of 2024 reached ¥3,577,825,097.29, reflecting a growth of 5.13% from ¥3,403,174,100.02 at the end of 2023[20]. - The company reported a basic earnings per share of ¥0.36 for 2024, a decrease of 42.86% from ¥0.63 in 2023[20]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥88,687,855.32, a decrease of 40.60% from ¥149,295,158.95 in 2023[20]. - The company achieved a cumulative investment progress of 100% for the acquisition of Guangzhou Longzhijie and 80% for Beijing Bohong[171]. - The company reported a total revenue of 30,876.72 million, showing a slight increase from 29,519.1 million in the previous period[173]. Governance and Compliance - The company emphasizes the importance of adhering to the disclosure requirements for the medical device industry as per the Shenzhen Stock Exchange guidelines[4]. - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions[4]. - The annual report is subject to review by the board and has been signed by key executives, ensuring its validity[4]. - The report indicates that all board members attended the meeting to review the annual report, reflecting strong governance practices[4]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, and financial management[199]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[193]. - The company has a dedicated investor relations management system to ensure fair information disclosure and communication with investors[197]. - The company has a structured approach to governance, enhancing its operational standards and promoting sustainable development[190]. Risk Management and Strategic Focus - The company has a comprehensive risk management strategy outlined in the report, particularly regarding future development prospects[4]. - The company is actively monitoring market trends and potential risks that may impact its future performance and strategic initiatives[4]. - The company has established a risk control system for R&D projects, conducting feasibility studies and regular tracking to mitigate risks[184]. - The company operates in technology-intensive sectors, facing risks in R&D such as direction deviation, cost overruns, and potential failure to commercialize products[184]. Innovation and Technology Development - The company has outlined its strategic focus on innovation and technology development in the automation control systems sector[4]. - The company has integrated advanced technologies such as IoT and AI to enhance the digitalization and intelligence of manufacturing processes[31]. - The company emphasizes continuous technological innovation and has developed various high-tech products, including a one-button disinfection system and an intelligent logistics system[83]. - The company is focusing on AI technology integration in industrial production to enhance operational efficiency and product quality[92]. - The company is developing an intelligent fermentation digitalization system aimed at real-time monitoring and control of fermentation parameters, which is expected to enhance production efficiency and reduce raw material consumption[111]. - The company is focusing on AI and digital twin technologies to solidify its leading position in the fermentation automation sector, addressing the industry's demand for intelligent upgrades[111]. - The company is committed to ongoing research and development to expand its portfolio of medical devices, ensuring compliance with regulatory standards and addressing market needs[134]. Market Trends and Competitive Landscape - The demand for industrial automation is experiencing structural differentiation, with emerging fields like synthetic biology and new materials showing significant growth potential[32]. - The industrial automation industry in China is experiencing intensified competition and increasing concentration, with international giants dominating the high-end market while local companies leverage technological innovation and cost control to break through in niche areas[33]. - The market for rehabilitation medical devices is characterized by a significant imbalance between supply and demand, driven by an aging population and rising chronic disease rates, leading to a strong and continuous growth momentum[39]. - The rehabilitation medical device industry is facing short-term pressure due to stricter governance and procurement delays, but long-term opportunities arise from a shift towards quality competition and compliance management[41]. - The dual drivers of demographic changes and health management upgrades are expected to inject strong momentum into the growth of the rehabilitation medical industry[43]. - The ongoing implementation of hierarchical medical policies is facilitating the penetration of rehabilitation devices into grassroots medical institutions, expanding market coverage[44]. Product Development and Offerings - The company has established a dual-driven development strategy focusing on intelligent manufacturing and rehabilitation medical equipment[30]. - The rehabilitation medical equipment segment has transitioned to providing comprehensive solutions, covering rehabilitation assessment, training, and physical therapy[61][62]. - The company offers specialized rehabilitation solutions across six major areas, addressing specific disease issues more effectively than single-device sales[64]. - The company aims to enhance its product line and expand sales channels, focusing on building a strong brand presence in the rehabilitation medical equipment market[70][73]. - The company is developing a high-end digital EEG machine targeting hospitals' neurology departments, with market demand analysis completed and domestic medical device registration achieved[125]. - The company is focusing on expanding its product line in the rehabilitation sector, particularly in community rehabilitation markets, to lead the industry towards precision and intelligence[123]. - The company has completed small batch production and received domestic medical device registration for several new products, enhancing its competitive edge in the market[119]. - The company is targeting the silver economy market with a new product designed for home rehabilitation of swallowing disorders, integrating biofeedback and safety monitoring systems[119]. Sales and Marketing Strategies - The company utilizes both distribution and direct sales models, with a focus on government procurement projects in the domestic market[82]. - The company is strategically expanding its marketing team in non-pharmaceutical sectors to strengthen its market presence and technical service capabilities[92]. - The company is actively expanding its distribution channels to include grassroots medical institutions, leveraging existing relationships to enhance market penetration[73]. - The company is focusing on brand awareness through academic promotion and has established the "Ivy Rehabilitation Ecosystem" for resource sharing[74]. Financial Management and Cash Flow - The company improved cash flow management significantly by optimizing long-term receivables recovery strategies, enhancing liquidity and overall fund turnover efficiency[90]. - The net cash flow from financing activities decreased by 104.97%, mainly due to a reduction in cash received from bank loans[149]. - The net increase in cash and cash equivalents was ¥118,901,719.34, representing a 93.12% increase from ¥61,567,584.92 in the previous year[148]. - The total amount of unused raised funds as of December 31, 2024, is ¥392.61 million, with ¥390 million allocated for temporary working capital[169]. Research and Development - In 2024, the company has 311 R&D personnel, a decrease of 9.59% from 344 in 2023, while the proportion of R&D personnel remains stable at 21.52%[126]. - R&D investment for 2024 amounts to approximately ¥89.67 million, representing 9.36% of operating revenue, an increase from 6.25% in 2023[127]. - The company has obtained a total of 106 domestic and international medical device registrations and certifications as of the end of 2024, with 16 new registrations added during the year[129]. - The company has received NMPA registrations for 38 medical devices, with the latest being the "Low Temperature Impact Pain Relief Device" registered on April 11, 2023, valid until April 10, 2028[130].

西南证券股份有限公司 关于北京诚益通控制技术集团股份有限公司 发行股份及支付现金购买资产并募集配套资金之募集资金 2024 年度募集资金存放与使用情况的核查意见 西南证券股份有限公司（以下简称"西南证券"或"独立财务顾问"）作为 北京诚益通控制技术集团股份有限公司（以下简称"诚益通"或"公司"）发行 股份及支付现金购买资产并募集配套资金之独立财务顾问，根据《上市公司重大 资产重组管理办法》、《上市公司并购重组独立财务顾问管理办法》、《深圳证券交 易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等有关规定，对公司 2024 年度募集资金存放与使用情 况进行了核查，相关意见如下： 一、募集资金基本情况 （一）募集资金的到位情况 经中国证券监督管理委员会《关于核准北京诚益通控制工程科技股份有限公 司向罗院龙等发行股份购买资产并募集配套资金的批复》（证监许可[2017]127 号）核准，公司向广州龙之杰科技有限公司（以下简称"广州龙之杰"）、北京诚 益通博日鸿智能装备技术有限公司（原名"北京博日鸿科技发展有限公司"，以下 简称"北京博日鸿"）原股东发行股份及支付现金 ...

北京诚益通控制技术集团股份有限公司 内控审计报告 大信审字[2025]第 2-00741 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 内部控制审计报告 大信审字[2025]第 2-00741 号 北京诚益通控制技术集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了北 京诚益通控制技术集团股份有限公司（以下简称"诚益通"）2024 年 12 月 31 日的财务报告内 部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是企业董事会的责任。 二、注册会计师的责任 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants LLP. Room2206 22/F,Xueyuan International Tower No.1 ZhichunRoad,Haid ...

北京诚益通控制技术集团股份有限公司 审 计 报 告 大信审字[2025]第 2-00740 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 审 计 报 告 大信审字[2025]第 2-00740 号 北京诚益通控制技术集团股份有限公司全体股东： 一、审计意见 我们审计了北京诚益通控制技术集团股份有限公司（以下简称"贵公司"）的财务报表， 包括 2024 年 12 月 31 日的合并及母公司资产负债表，20 ...

北京诚益通控制技术集团股份有限公司 募集资金存放与实际 使用情况审核报告 大信专审字[2025]第 2-00170 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 我们的责任是在实施审核工作的基础上对贵公司编制的募集资金存放与实际使用情况专 项报告发表审核意见。我们按照《中国注册会计师其他鉴证业务准则第 3101 号—历史财务信 息审计或审阅以外的鉴证业务》的规定执行了审核业务。该准则要求我们计划和实施审核工 作，以对贵公司编制的募集资金存放与实际使用情况专项报告是否不存在重大错报获取合理 保证。在审核过程中，我们实施了包括询问、检查有关资料与文件、抽查会计记录等我们认 为必要的审核程序。我们相信，我们的审核工作为发表审核意见提供了合理的基础。 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Ro ...

经中国证券监督管理委员会《关于核准北京诚益通控制工程科技股份有限公 司向罗院龙等发行股份购买资产并募集配套资金的批复》（证监许可[2017]127 号）核准，公司向广州龙之杰科技有限公司（以下简称"龙之杰"）、北京博日 鸿科技发展有限公司（以下简称"博日鸿"）原股东发行股份及支付现金购买其 持有的龙之杰、博日鸿100%股权，并向特定投资者发行人民币普通股6,577,900 股，发行价格46.94元/股,募集资金总额人民币308,766,626.00元，扣除承销费、律 师费、资产评估费、审计费等发行费用14,141,672.88元后，剔除承销费用对应的 增值税566,037.74元，实际募集资金净额为295,190,990.86元。上述资金到位情况 已经大信会计师事务所（特殊普通合伙）验证，并出具了大信验字[2017]第2-00028 号验资报告。 西南证券股份有限公司 关于北京诚益通控制技术集团股份有限公司 部分募集资金永久补充流动资金的核查意见 西南证券股份有限公司（以下简称"西南证券"或"独立财务顾问"）作为 北京诚益通控制技术集团股份有限公司（以下简称"诚益通"或"公司"）发行 股份及支付现金购买资产并 ...

北京诚益通控制技术集团股份有限公司 非经营性资金占用及其他关联资金 往来情况汇总表的专项审计报告 大信专审字[2025]第 2-00171 号 大信专审字[2025]第 2-00171 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants LLP. Room2206 22/F,Xueyuan International Tower No.1 ZhichunRoad,Haidian Dist. Beijing,China,100083 电话 Telephone： +86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 非经营性资金占用及其他关联资金往来情况汇总表 的专项审计报告 北京诚益通控制技术集团股份有限公司全体股东： 我们接受委托，审计了北京诚益通控制技术集团股份有限公司（以下简称" ...

诚益通（300430）公告，公司控股股东立威特持有的528.39万股股份已解除质押，占其所持股份的 10.32%，占公司总股本的1.94%。本次解除质押不涉及重大资产重组等业绩补偿义务，亦不会导致公司 实际控制权发生变更。 ...